Vascepa (icosapent ethyl) is a prescription medication approved by the FDA for the treatment of severe hypertriglyceridemia, or extremely high levels of triglycerides in the blood [1]. While the long-term benefits of using Vascepa are still being studied, there are some potential advantages that have been identified through clinical trials and research.

One of the primary benefits of using Vascepa long-term is its ability to lower triglyceride levels. High triglyceride levels can increase the risk of heart disease, stroke, and other cardiovascular problems [2]. By reducing triglyceride levels, Vascepa can help to lower the risk of these complications.

In addition, recent studies have suggested that Vascepa may offer additional cardiovascular benefits beyond its triglyceride-lowering effects. For example, a large-scale clinical trial known as REDUCE-IT found that Vascepa significantly reduced the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death, in patients with elevated triglyceride levels who were already taking statins [3].

It is important to note that while these potential benefits are promising, they are not yet fully understood, and more research is needed to fully understand the long-term effects of using Vascepa. Additionally, as with any medication, Vascepa can have side effects, and it is important to speak with a healthcare provider to determine whether it is the right treatment option.

In summary, the long-term benefits of using Vascepa may include lowering triglyceride levels and potentially reducing the risk of cardiovascular events. However, more research is needed to fully understand the long-term effects of this medication.

Sources:

1. Vascepa (icosapent ethyl) [Prescribing Information]. Amarin Pharma, Inc.; 2021. Available at: <https://www.vascepa.com/pdf/VASCEPA-PI.pdf>.
2. National Heart, Lung, and Blood Institute. High Blood Triglycerides. <https://www.nhlbi.nih.gov/health-topics/high-blood-cholesterol/high-blood-triglycerides>.
3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812797. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa1812797>.
4. DrugPatentWatch. Vascepa (icosapent ethyl) [Patent Information]. <https://www.drugpatentwatch.com/drugs/vascepa>.